Tag:
Parkinson's
Latest Headlines
Latest Headlines
University of Alabama begins Parkinson's biomarker study
Researchers at the University of Alabama are investigating whether a reduced sense of smell, or hyposmia, could be used as a biomarker to help detect Parkinson's disease.
Impax calls on former Teva, Watson execs to confront FDA issues
Having failed so far to get its extended-release Parkinson's drug Rytary to market, Impax Laboratories ($IPXL) is turning to asking three big-name specialists what it should do.
Impax brings in big guns to get on top of manufacturing problems
Impax Laboratories is bringing in the big guns to help it accomplish what it has been unable to do on its own.
Israeli team spurs nerve healing with implant-released gel
A team of researchers at Tel Aviv University has developed a biodegradable implant that delivers a gel capable of restoring healthy nerve function to treat diseases such as Parkinson's.
International Parkinson's biomarkers trial begins
A massive, international study to find and evaluate potential Parkinson's disease biomarkers has finished enrolling a first group of 600 Parkinson's patients and controls.
Researchers reverse Parkinson's damage with nasal gene delivery
Researchers at Northeastern University have developed a treatment for Parkinson's disease meant to revive dying neurons in the brain via delivery through the nose.
Civitas' inhaled Parkinson's drug promises novel delivery with positive PhII results
Civitas Therapeutics heralded a successful Phase II trial result for its inhaled Parkinson's drug CVT-301, the novel delivery of which promises to make the disease more manageable for patients on an everyday basis, the company says.
DBS helped some anorexia patients eat more
A deep brain stimulation implant used in a small pilot study helped some patients with severe anorexia gain weight and boosted their mood.
NIH pours $900K into Parkinson's biomarker research
NIH is looping Emory's Rollins School of Public Health into its Parkinson's Disease Biomarker Program, pledging $900,000 to a research team aiming to discover new ways of identifying the ailment.
FDA stiff-arms Impax on extended-release Parkinson's combo
The FDA has thrown up a roadblock for Impax Laboratories' ($IPXL) extended-release version of a carbidopa-levodopa combo for Parkinson's disease now dubbed Rytary.
